Frexalimab is under clinical development by Sanofi and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData, Phase III drugs for Relapsing Multiple Sclerosis (RMS) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Frexalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Frexalimab overview
Frexalimab (INX-021) is under development for the treatment of autoimmune diseases including relapsing multiple sclerosis, relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), active systemic lupus erythematosus (SLE), focal segmental glomerulosclerosis (FSGS) and type 1 diabetes. It is administered through intravenous and subcutaneous route. The therapeutic candidate is a re-engineered antagonist antibody that acts on CD40.
It was under development for primary Sjogren's syndrome disease.
Sanofi overview
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi’s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has an operational presence in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
For a complete picture of Frexalimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
